Last reviewed · How we verify
Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure
With this research the Investigators hope to learn if early aquapheresis in an outpatient setting will improve congestive heart failure symptoms in outpatients with decompensated heart failure who have been refractory to high dose diuretics. In previous trials in inpatient settings, aquapheresis has been demonstrated to improve quality of life and reduce hospital visits for those who have undergone the treatment. This study is one of the first to evaluate the effectiveness of aquapheresis in veterans with congestive heart failure in an outpatient setting. The aquapheresis device, Aquadex FlexFlow® System, manufactured by CHF Solutions™, Minneapolis, MN, has been approved by the Food and Drug Administration (FDA) for removing excess sodium and fluid from patients suffering from volume overload, like in congestive heart failure.
Details
| Lead sponsor | Ramona Gelzer Bell |
|---|---|
| Phase | NA |
| Status | WITHDRAWN |
| Start date | Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Heart Failure
- Congestive Heart Failure
- Decompensated Heart Failure
Interventions
- Aquapheresis
- IV Diuretics